Regulatory-grade clinical trial design using real-world data

被引:14
作者
Levenson, Mark S. [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
关键词
Evidence; bias; heterogeneity; real-world;
D O I
10.1177/1740774520905576
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.
引用
收藏
页码:377 / 382
页数:6
相关论文
共 22 条
  • [1] [Anonymous], 2001, GUID IND E10 CHOIC C
  • [2] [Anonymous], 1998, GUID IND E9 STAT PRI
  • [3] [Anonymous], 2013, GUID IND FDA STAFF B
  • [4] Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study
    Barry, Sarah J. E.
    Dinnett, Eleanor
    Kean, Sharon
    Gaw, Allan
    Ford, Ian
    [J]. PLOS ONE, 2013, 8 (09):
  • [5] FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial
    Cocoros, Noelle M.
    Pokorney, Sean D.
    Haynes, Kevin
    Garcia, Crystal
    Al-Khalidi, Hussein R.
    Al-Khatib, Sana M.
    Archdeacon, Patrick
    Goldsack, Jennifer C.
    Harkins, Thomas
    Lin, Nancy D.
    Martin, David
    McCall, Debbe
    Nair, Vinit
    Parlett, Lauren
    Temple, Robert
    McMahill-Walraven, Cheryl
    Granger, Christopher B.
    Platt, Richard
    [J]. CLINICAL TRIALS, 2019, 16 (01) : 90 - 97
  • [6] Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
    Curtis, Melissa D.
    Griffith, Sandra D.
    Tucker, Melisa
    Taylor, Michael D.
    Capra, William B.
    Carrigan, Gillis
    Holzman, Ben
    Torres, Aracelis Z.
    You, Paul
    Arnieri, Brandon
    Abernethy, Amy P.
    [J]. HEALTH SERVICES RESEARCH, 2018, 53 (06) : 4460 - 4476
  • [7] Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy 20-Year Follow-Up of West of Scotland Coronary Prevention Study
    Ford, Ian
    Murray, Heather
    McCowan, Colin
    Packard, Chris J.
    [J]. CIRCULATION, 2016, 133 (11) : 1073 - 1080
  • [8] Franklin JM, 2019, CLIN PHARMACOL THER, DOI [10.1002/cpt.1633., DOI 10.1002/CPT.1633.]
  • [9] Cautions as Regulators Move to End Exclusive Reliance on Intention to Treat
    Hernan, Miguel A.
    Scharfstein, Daniel
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (07) : 515 - +
  • [10] Per-Protocol Analyses of Pragmatic Trials
    Hernan, Miguel A.
    Robins, James M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14) : 1391 - 1398